"The Retina Institute of St. Louis, St. Lukes Location"

During the past decade, The Retina Institute conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 14 clinical trials were completed, i.e. on average, 63.6% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 10 clinical trials were completed. i.e. 111.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Retina Institute" #1 sponsor was "Jaeb Center for Health Research" with 16 trials, followed by "Barnes Retina Institute" with 8 trials sponsored, "Genentech, Inc." with 5 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored and "Retina Research Institute, LLC" with 4 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Retina Institute" #1 collaborator was "National Eye Institute (NEI)" with 17 trials as a collaborator, "National Institutes of Health (NIH)" with 7 trials as a collaborator, "Genentech, Inc." with 5 trials as a collaborator, "Allergan" with 4 trials as a collaborator and "Juvenile Diabetes Research Foundation" with 3 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "The Retina Institute" are "Diabetic Macular Edema" (10 trials), "Geographic Atrophy" (5 trials), "Diabetic Retinopathy" (4 trials), "Macular Edema" (4 trials) and "Proliferative Diabetic Retinopathy" (3 trials). Many other conditions were trialed in "The Retina Institute" in a lesser frequency.

Most popular intervention types in "The Retina Institute" are "Drug" (34 trials), "Procedure" (7 trials), "Other" (5 trials), "Device" (3 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Galegenimab" (2 trials), "Lampalizumab" (2 trials), "Placebo" (2 trials), "Ranibizumab" (2 trials) and "bevacizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "The Retina Institute" are 45 trials for "All" genders.

Currently, there are NaN active trials in "The Retina Institute". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in The Retina Institute, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in The Retina Institute, 3 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 8 trials that are defined as “Not Applicable".